Analyst Michael Matson of Needham maintained a Buy rating on Insight Molecular Diagnostics, retaining the price target of $9.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Michael Matson has given his Buy rating due to a combination of factors, primarily the strong commercial traction of GraftAssureIQ and the rapid adoption by 37 centers in 4Q25, significantly exceeding prior targets. He also views the March 2026 de novo submission of GraftAssureDx to the FDA as a key catalyst, with the review process potentially unlocking a sizable regulated testing opportunity.
In addition, Matson highlights the robust interest from 28 transplant centers in the 5,000-patient GraftAssureCore registry, which suggests durable clinical demand and incremental revenue potential. He further notes that IMDX’s strengthened balance sheet, with roughly $39M in cash after the recent raise and a manageable quarterly burn near $7.5M, should adequately fund commercialization plans and support value creation through upcoming milestones.